{"name":"GPCR Therapeutics, Inc.","slug":"gpcr-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"GPCR Therapeutics, Inc. is a biotechnology company focused on the discovery and development of novel small molecule drugs targeting G protein-coupled receptors (GPCRs). The company has a pipeline of five drug candidates, with several in Phase 2 clinical trials, aiming to address significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-07","type":"deal","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (BBOT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (BBOT), Structure Therapeutics, Inc. Sp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxObVFCa1BTWGtCbFp1Z3d3aVpiNWcyWl9DOUhGYkVqTTVCY2V6Q0FJLVExV3hJZEJSbDBmc3d3ZTljZmxLSVBQM3BmcHJlU1g0R0V0T0w2X1l3VXkzRnFDd2JqajBsVFBLaTZzVEt5OGxYYUhLMEFnVmwwS3ZITTZpSVBrdW5vTTdLcHYyZDgxUTg4RlhISHlodHRnbGEzWWY4QWl6TzBfV3F3aFIzbGR2Sk5YM25pVVJDN3BYMHJubU5CRDJfQ2ZrSjhGczRscjBKeEtBYjByUmlkaXRkVWJ3aDhRcVppUlJET2R2OFVyWmVwQQ?oc=5","date":"2026-03-05","type":"deal","source":"Stocktwits","summary":"VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits","headline":"VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNSi1EMVp0ZmFfamk0UGh6QzVUVXhJa0ZhVVlhbXMzcGFLbDV6eUo5c2FyZlQ5aFphRk1wWlNqZWlnd19yVktUYjFpRGJ5eXBSRDRwNWtvZnpaaXFBelRDaUl2LWJCaEZ0eWNiSmxhNkpkLXVLRmMzaUxkbW5yZkJKV3JuLWJxNG51am9tRU9FQlc3RGhRcmdHNUl5cEU1cmJqSG94ZlNEMnB4VVJ2eElLR3hQR2o0YlUxZzNucG4xUQ?oc=5","date":"2026-02-23","type":"pipeline","source":"Investing News Network","summary":"Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board - Investing News Network","headline":"Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTFNGemt1cnhpUE1Ba0p6dUFxNmxLR1lveHFURFotOVRxaDl0VFVMcW8yb3FPQk92cEk1NElmcjUxZXRuM1dnVHNtREFsYjVCMjNsT1VBSUpiVWRXdE1DVVF1M3k4aGtQR3ZBX2Z3Q3JpN1RzVHZXZmp5OVQwYmJRTngydjdMUHM2?oc=5","date":"2026-02-12","type":"deal","source":"Yahoo Finance","summary":"Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company - Yahoo Finance","headline":"Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNQU1KaVhFTDVKUlQ3S1A1alMyUURKRW9yYWlha3ZVek11eURoMG02MjVhUzZydElIMDhXTjRNNTE5dzVzcnd0WEphRjVuSU1lZWpfeVUyc1d0VlZVbXpENU9BcGlvYkRTb3lCZXA2eDRzUmdSRmg2SGEzNU1NYVpaOGJmdU5PMHdra1Rr?oc=5","date":"2026-01-29","type":"pipeline","source":"etfdb.com","summary":"Biotech M&A Wave Positions SBIO for Growth - etfdb.com","headline":"Biotech M&A Wave Positions SBIO for Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE41SkdaSHF5Tlpmdmp3Mk5WcW1xS2MxREdEU0pDXzJSNC1seVM3bnQzMW9UTTVKdnF4aTdqUUJ2eHFlZG1kazRTZjJOOHNiVUNOZ1Iw?oc=5","date":"2026-01-26","type":"pipeline","source":"Stock Titan","summary":"CRNX Stock Price, News & Analysis - Stock Titan","headline":"CRNX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNd3ZPSTFtcFRqYnJRZXpFV2E3T1lQelBZSXRBVFNvYUVKVmNRQXJhRFJLQUR3RmRDS2pKZmt0OWhWYlM1cm0zS1p5akFhUC00SFRiNVl4OTY5VTNoeG41ZU1SZ01mamItNTVZMC1rZG9jSHY1TkYybXhZellHc0ZwdDdOT1p6d1Z3Z2xlaVc0SEw2SHE1ZXBha25CaXhsTzA?oc=5","date":"2026-01-13","type":"pipeline","source":"The Motley Fool","summary":"A 10% Owner Of Structure Therapeutics Shed Shares - The Motley Fool","headline":"A 10% Owner Of Structure Therapeutics Shed Shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPQW9BZGQzcUR3SkNYcENzMEJDUURUWWRSQ2g0Q19tYzJfVlN6R0gzVlVIVkhUOGpHWW5zOW1HWWlJbWxHNXplQTRodTVlaWhGMklDSGVGMzFGbk5ZblRrX1djV2NZVHY5QnB1ZGtQTGtkTTU1VXRIR3JLSE43dnozeHdVbmY0a3ZCcHFJZjVqdmdVdFVlUV9xN3Y3RmY4RTUz?oc=5","date":"2026-01-06","type":"deal","source":"The Pharma Letter","summary":"Structure Therapeutics signs patent deal with Genentech - The Pharma Letter","headline":"Structure Therapeutics signs patent deal with Genentech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNLUZ1V3d0MkJBUFg1QjZRUFIyb2Q3cVJmdEpNcWhwcmtkQ3Fnb0tQNmhheUh4M2hfRGt2YjVBTkhiX2pIQkNYcW9sWDdkR3JfbW1HcS1xdnNaamlTbGZibnFhMkg3MGhHcVlYM0xQOXBTTS1RbFk0bHoyWjB5MjJRNGc1akZaQ0tmSEtyNnlleUpVMjlaZExIdTZpT2lyMVFSSGktV01SQmpRMEdWTUxzOWNsZ1piUHBNb1RFYkN6R2VoRld4Tk1ib2dfVkoyek9vU2d5Q0RBUmFuOVlYT2FhNzJLLWZsVmZHeWVIVFNDaVFidw?oc=5","date":"2025-12-23","type":"pipeline","source":"TechStock²","summary":"Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next - TechStock²","headline":"Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQVmt0dTQwMFV3SnExeVY2Tlg4aEwzZlJqdWlLT0pTYWFjU2tHcUppTmtYS0RLbDZwUHhleGtoR2szX0F4TG0yQVV5OGdJanVsR19XR0ttSURjbVJlNlpOSGNLbDhNVTN2WkZUZlZzUVZPdkNSaVN4X3h0UG13UTEwMGxPSHRuajVZTllDMmhDTjlhNExxWERwazFpU29TcGNDMExLMnlYZmF0dw?oc=5","date":"2025-10-03","type":"pipeline","source":"Seeking Alpha","summary":"Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena (NASDAQ:GPCR) - Seeking Alpha","headline":"Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena (NASDAQ:GPCR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBpVW52emlrWTRBUlY0OV9wejhhNmx1VDZCYmEybmtadGQ4UVFCZlN5ejFIbTJfNXFiTXJ6WVh1VmlONWI4a3p6anV0YjlscVl3cWd5czNQNlU5QTh5S2JjYmxJR1hnNDFObmN4Qi1n0gFyQVVfeXFMTkdyRWUzQWVtZzlxdEhVanV3dFFJV0ZxdGZHRm5NSDlvSVp0bWdpOUhvMENUbnZuWFlLOUdubzJHRDZMOXF3OERJN1ZNc1dMVWM0RFBFUHlocW43QkZlbXhBNXNwMHJSZ1ZwTjFBenhMMHJ3?oc=5","date":"2025-07-11","type":"pipeline","source":"koreabiomed.com","summary":"Yuhan expands obesity pipeline with next-gen drugs, reformulated therapies - koreabiomed.com","headline":"Yuhan expands obesity pipeline with next-gen drugs, reformulated therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOUGl5WFQ3dHpxazY2T0NTWDdCbWN2bDlxZFVWaFh3Um52bUJGbzRTVnFhSEplYk5WaHFidDZGMngxend4cFBZbncyWWhwekkyWV9sMjdYbENKV1JnbnRPRmtnYTZ2dkFTUGkzZGRRQ3NvTzNRLUlsZzRfUUFKZFg0eWV1MXpLeURQMXVxRFMwaXJYRGY1QXlj?oc=5","date":"2024-10-29","type":"pipeline","source":"Labiotech.eu","summary":"GPCR therapies: Eight promising biotechs hacking the cell signaling pathway - Labiotech.eu","headline":"GPCR therapies: Eight promising biotechs hacking the cell signaling pathway","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}